4//SEC Filing
von Moltke Lisa 4
Accession 0000950170-24-128626
CIK 0001609809other
Filed
Nov 18, 7:00 PM ET
Accepted
Nov 19, 4:20 PM ET
Size
9.3 KB
Accession
0000950170-24-128626
Insider Transaction Report
Form 4
von Moltke Lisa
See Remarks
Transactions
- Exercise/Conversion
Common Stock
2024-11-15+2,969→ 33,392 total - Exercise/Conversion
Restricted Stock Units
2024-11-15−2,969→ 26,719 total→ Common Stock (2,969 underlying) - Sale
Common Stock
2024-11-18$0.54/sh−977$528→ 32,415 total
Footnotes (4)
- [F1]Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 11, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
- [F3]The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.5406 to $0.5442, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
Documents
Issuer
Seres Therapeutics, Inc.
CIK 0001609809
Entity typeother
Related Parties
1- filerCIK 0001808592
Filing Metadata
- Form type
- 4
- Filed
- Nov 18, 7:00 PM ET
- Accepted
- Nov 19, 4:20 PM ET
- Size
- 9.3 KB